Market Indices
Sector Heatmap
PYPD — PolyPid Ltd. Ordinary Shares
NasdaqPolyPid Ltd. Ordinary Shares
- O
- 5.11
- H
- 5.19
- L
- 4.90
- V
- 113.43K
PYPD — Latest News & Headlines
8 StoriesA treatment designed to prevent infections after abdominal surgery enters European review - Stock Titan
A treatment designed to prevent infections after abdominal surgery enters European review Stock Titan
Understanding Momentum Shifts in (PYPD) - Stock Traders Daily
Understanding Momentum Shifts in (PYPD) Stock Traders Daily
PolyPid Announces Termination of ADVANZ PHARMA Europe Agreement for D-PLEX100, Regains European Rights - Quiver Quantitative
PolyPid Announces Termination of ADVANZ PHARMA Europe Agreement for D-PLEX100, Regains European Rights Quiver Quantitative
A drug designed to release antibiotics for 30 days clears an EU review step at PolyPid (PYPD). - Stock Titan
A drug designed to release antibiotics for 30 days clears an EU review step at PolyPid (PYPD). Stock Titan
PolyPid regains European rights for D-PLEX after deal ends By Investing.com - Investing.com South Africa
PolyPid regains European rights for D-PLEX after deal ends By Investing.com Investing.com South Africa
PolyPid stock faces FDA and EMA decisions for D-PLEX100 - AD HOC NEWS
PolyPid stock faces FDA and EMA decisions for D-PLEX100 AD HOC NEWS
A European licensing deal ends by mutual agreement between PolyPid (PYPD) and ADVANZ PHARMA. - Stock Titan
A European licensing deal ends by mutual agreement between PolyPid (PYPD) and ADVANZ PHARMA. Stock Titan
PolyPid regains Europe rights: what it means for PolyPid stock - AD HOC NEWS
PolyPid regains Europe rights: what it means for PolyPid stock AD HOC NEWS